LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update
On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027BOTHELL, Wash., Nov. 16, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. NASDAQ:LONA, a clinical-stag…